Comparing Thermal Therapy Using MiBo Thermoflo Versus Warm Compresses and Eyelid Massage for Treating Meibomian Gland Dysfunction

What this Trial Is About

Dry eye syndrome affects about 10 to 20% of people worldwide, with meibomian gland dysfunction MGD being a common cause. MGD occurs when the small glands in the eyelids that produce oils for the tear film become blocked or change, leading to faster tear evaporation and symptoms like eye irritation and inflammation. This study is evaluating whether thermal therapy using the MiBo Thermoflo device works better than the standard treatment of warm compresses and eyelid massage for dry eye caused by MGD. Participants will be randomly assigned to one of two treatment groups to compare these approaches over 24 weeks. One group will receive three sessions of thermal therapy with the MiBo Thermoflo device, each session 11 minutes per eye, spaced two weeks apart. The other group will use warm compresses and perform eyelid massage twice daily for 11 minutes per eye. Both groups will continue their usual dry eye care as needed during the study period. This design allows researchers to assess differences in treatment effects over time. Participants will be followed for 24 weeks, during which various eye health measures will be regularly checked. These include tests of gland function, tear quality and stability, eye surface staining, symptom questionnaires, and tear composition. Researchers will monitor safety and any adverse events throughout the study. The goal is to see if thermal therapy provides better relief and improvement compared to traditional warm compresses and massage therapy.

Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction